The U.S. Food and Drug Administration has given Medtronic (NYSE:MDT) the go-ahead on a clinical trial to test its next generation of MRI pacemaker technology, the Minnesota company announced Monday.

The U.S. FDA recently granted Medtronic plc approval for its deep brain stimulation (DBS) system to be used to treat Parkinson’s disease or essential tremor while a patient is asleep, under general ...

Medical device company Medtronic has introduced in Europe a line of spinal cord stimulators for chronic back and leg pain that are compatible with magnetic resonance imaging, according to American ...

IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more. Pacemakers are small oval-shaped ...

Rechargeable neurostimulator joins the Medtronic Percept™ family – the first and only deep brain stimulation system with sensing, directionality, and advanced programming. "Our DBS therapy with ...

Medtronic plc is the first company to receive US Food and Drug Administration (FDA) approval for its suite of cardiac rhythm and heart failure devices and leads to be scanned in both 3 and 1.5 Tesla ...

Medtronic (NYSE:MDT) said the FDA has approved its extravascular implantable cardioverter-defibrillator the Aurora EV-ICD MRI SureScan, along with the Epsila EV MRI SureScan defibrillation lead for ...

DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (MDT) (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's ...

NEW YORK — Medtronic said Monday that it was cleared to market a heart defibrillator implant that can be safely used in an MRI scanner. Medtronic’s Evera SureScan is designated “MR conditional,” which ...